ESH Video

ESH International Conference on New concepts in B Cell Malignancies: from molecular pathogenesis to personalized treatment

Chairs: Michael Hallek, Louis Staudt, Stephan Stilgenbauer
Local Organizer: Kostas Stamatopoulos

 

SESSION I: MOLECULAR GENETICS AND PROFILING – WHAT HAVE WE LEARNED?

Pathogenic and therapeutic relevance of molecular signatures in aggressive lymphoma – G. Lenz

Genomic profiling and evolution of CLL – C. Wu

Molecular pathogenesis and treatment options in ALL – E. Campo

Genome, methylome and transcriptome sequencing in follicle center cell lymphoma (ICGC) – R. Siebert

Bcl-6 and related pathways in lymphoma genesis – R. Dalla-Favera

 

SESSION II: MOLECULAR PATHOGENESIS OF LYMPHOMA

Genomic profiling and the discovery of important pathways in lymphoma – R. Gascoyne

B cell receptor mediated signaling and targeted therapies – L. Staudt

B cell development and transformation: focus on the germinal center – R. Küppers

Mantle cell lymphoma – C. Mullighan

 

SESSION III: PROGNOSTIC MARKERS AND STAGING IN LYMPHOMA AND CLL – CONTROVERSIAL DEBATES

Diffuse large cell lymphoma:
Do we still need a clinical staging or can it be replaced by molecular signatures or profiling of the tumor?

Pro staging – M. Pfreundschuh

Pro molecular profiling – R. Gascoyne

 

Indolent lymphoma (follicular lymphoma)
The end of Ann Arbor staging and the beginning of molecular staging has come

Yes – G. Salles

No – F. Morschhauser

 

CLL:
The end of clinical staging alone has come – every treatment decision will be made after genetic profiling?

Yes – S. Stilgenbauer

No – E. Montserrat

 

SESSION IV: CONVENTIONAL CHEMO (IMMUNE) THERAPIES – STATE OF THE ART 2014

Diffuse large cell lymphoma – G. Salles

Indolent lymphoma – G. Salles

CLL – M. Hallek

Hodgkin – P. Borchmann

 

SESSION V: STEM CELL TRANSPLANTATION IN LYMPHOID MALIGNANCIES –
THE TIME IS OVER (OR NOT)? CONTROVERSIAL DEBATES

DLBCL

Pro transplant – U. Vitolo

Contra transplant – M. Pfreundschuh

 

Indolent Lymphomas

Pro transplant – S. Montoto

Contra transplant – M. Federico

 

CLL

Pro transplant – P. Dreger

Contra transplant – J. Gribben

 

SESSION VI: NOVEL THERAPEUTICS TARGETING DISTINCT KINASES OR PATHWAYS IN LYMPHOID MALIGNANCIES

BCL-2 inhibitors – J. Seymour

BTK inhibitors in CLL – P. Hillmen

BTK inhibitors in mantle cell lymphoma – S. Rule

BTK inhibitors in Waldenströms macroglobulinemia – S. Treon

Alternative BTK inhibitors (other than ibrutinib) – J. Brown

PI3K inhibitors – R. Furman

Novel type 2 antibodies – V. Goede

CART – D. Porter

Bispecific antibodies – R. Bargou

Antibody-drug conjugates – F. Morschhauser

 

SESSION VII: STRATEGIES FOR FUTURE CLINICAL TRIALS AND CONCEPTS FOR LYMPHOMA TREATMENT

Diffuse large cell lymphoma – K. Dunleavy

CLL – P. Hillmen

Mantle cell lymphoma – M. Dreyling

Follicular lymphoma. LYSA – G. Salles

 

 

 

 

 

 

 
Multiple Myeloma Hub Let's keep in touch! Clinical Updates on Acute Leukemias